Flutter Entertainment beats Q3 earnings estimate despite sports results impact
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics business, purchased 1,063,000 of its ordinary shares at 26 pence per share on October 29, according to a company press release issued Thursday.
The shares acquired in the buyback will be held in treasury. Following the purchase, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 6,738,252 shares held in treasury. The total number of shares carrying voting rights is now 442,355,538.
The transaction included the acquisition of 313,000 ordinary shares from Harwood, which acted as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The company purchased 104,333 shares from Oryx and 208,667 shares from North Atlantic Smaller Companies.
According to the release, Harwood facilitated this transaction to ensure that the aggregate indirect beneficial interest of Christopher Mills, a Non-Executive Director of EKF, remains at approximately the same level and does not exceed 30% of the total voting rights in the company following the repurchases. After the transaction, Mills’ aggregate indirect interest in the company stands at 130,443,000 ordinary shares.
EKF Diagnostics operates five manufacturing sites across the US and Germany and sells into more than 120 countries worldwide. The company focuses on point-of-care analyzers in hematology and diabetes, as well as life sciences services providing specialized manufacture of enzymes and custom products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.